July 23, 2024

Medical Trend

Medical News and Medical Resources

A COVID-19 vaccine from China long stable at 2 to 8 °C

A COVID-19 vaccine from China long stable at 2 to 8 °C

A COVID-19 vaccine from China CanSinoBio  long stable at 2 to 8 °C. Recently, two overseas mRNA COVID-19 vaccines have announced that they are more than 90% effective. However, due to the stringent cold chain storage requirements of this type of vaccine, the outside world is worried about its future transportation, distribution and cost.

On November 20th, at the third day of the Healthcare Forum on the third day of the 2020 Qiming Venture Capital 12th CEO Cloud Summit Week, Yu Xuefeng, co-founder, chairman and CEO of CanSino Bio, talked about the COVID-19 vaccine storage The temperature said: “Our vaccine is stable for a long time at 2 to 8 degrees Celsius, which brings great convenience to use.”


It is reported that CansinoBio is cooperating with the team of Academician Chen Wei of the Institute of Bioengineering of the Academy of Military Sciences of the Academy of Military Sciences to develop a recombinant COVID-19 vaccine (adenovirus vector).

Yu Xuefeng also mentioned in the dialogue session that the COVID-19 vaccine poses a new challenge to all vaccine companies in the world, including supervision and national regulatory agencies.

“If every Chinese takes the (COVID-19 vaccine), the output we may need in a year will be several billion, because some people may need two or even three shots.” Yu Xuefeng said, this is not in Chinese history. I have encountered such a problem, “In the past for routine immunization, our country’s annual vaccine production capacity was 100 million doses, and no more than 200 million doses. Suddenly, billions of doses were required, which would be huge for all vaccine companies Pressure and challenges”.

“For national regulatory agencies, even batch issuance is a huge challenge. Because we have only issued 100 million or 200 million batches in the past year, and now we are going to issue billions of billions, these require a lot of resource investment and It’s not a simple matter.” Yu Xuefeng said.

CanSino Bio is currently conducting Phase III clinical trials in Russia, Pakistan, Mexico and other countries. Yu Xuefeng said that everything is progressing smoothly.

It is worth mentioning that in May of this year, the COVID-19 vaccine co-operated with the Institute of Bioengineering of the Academy of Military Medicine of the Academy of Military Sciences was approved by the military for special medicines.

Yu Xuefeng revealed that many military personnel, especially peacekeepers, have been vaccinated with the vaccine. No case of infected vaccinators has been found, including peacekeepers in epidemic areas and direct contact with local people. Confidence is still pretty big, of course, the final conclusion must be explained by scientific data.”